A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Clinical Efficacy of an mRNA Based Seasonal Influenza Vaccine in Older Adults ≥65 Years of Age
GlaxoSmithKline
54,000 participants
Sep 2, 2026
INTERVENTIONAL
Conditions
Summary
This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single-dose intramuscular administration of the season-adapted investigational mRNA Seasonal Flu vaccine.
Single-dose intramuscular administration of an age-appropriate and season-adapted licensed influenza vaccine used as the active comparator.
Locations(163)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07805707